Page 51 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

REFERENCES

1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice
parameter: early detection of dementia: mild cognitive impairment (an evidence-based
review). Report of the Quality Standards Subcommittee of the American Academy of
Neurology. Neurology 2001;56(9):1133-42.
2. Knopman D. Pharmacotheraphy for Alzheimer's disease. Curr Neurol Neurosci Rep
2001;1(5):428-34.
3. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer's disease in the US
population: prevalence estimates using the 2000 Census. Arch Neurol 2003;60:1119-22.
4. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public
health impact of Alzheimer's disease, 2000-2050: potential implication of treatment
advances. Annu Rev Public Health 2002;23:213-31.
5. Wimo A, Winbald B. Health economical aspects of Alzheimer's and its treatment.
Psychogeriatrics 2001;1:189-193.
6. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for
managing Alzheimer's disease: Part II. Treatment. Am Fam Physician 2002;65(12):2525-34.
7. Giacobini E, editor. Cholinesterases and cholinesterase-inhibitors. London: Martin Dunitz;
2000.
8. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, et
al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
Acta Neurol Scand Suppl 2000;176:68-73.
9. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission
and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry
1988;12(4):421-30.
10. Bowen DM, Steele JE, Lowe SL, Palmer AM. Tacrine in relation to amino acid transmitters
in Alzheimer's disease. Adv Neurol 1990;51:91-6.
11. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for
neurologic disorders. N Engl J Med 1994;330(9):613-22.
12. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the
treatment of Alzheimer's disease. CNS Drug Rev 2003;9(3):275-308.
13. Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003;20(6):465-76; discussion 477-8.
14. Grimley Evans J, Wilcock G, Birks J. Evidence-based pharmacotherapy of AD. International
Journal of Neuropsychopharmacology 2004;7:351-69.
15. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
Clin Ther 2004;26(5):615-30.
16. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice
parameter: management of dementia (an evidence-based review). Report of the Quality
Standards Subcommittee of the American Academy of Neurology. Neurology
2001;56(9):1154-66.
17. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of
reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality
of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
18. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current
methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med
2001;20(3 Suppl):21-35.

Alzheimer's Drugs Page 51 of 205